Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 22,439 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pathologic Processes Clear all
Completed No phase listed Observational

Cirrhotics Undergoing General Surgery

NCT05202457
View directory record Official record
Conditions
Cirrhosis, Liver
Interventions
Elective surgery
Procedure
Lead sponsor
Danny Lascano
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 21, 2026, 4:47 AM EDT
Completed Phase 1 Interventional

Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma

NCT00718601
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Imetelstat Sodium (GRN163L)
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Detroit, Michigan • New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Oct 21, 2026, 4:47 AM EDT
Recruiting Phase 2 Interventional

IA Lidocaine and Methylprednisolone for Headache Associated With Subarachnoid Hemorrhage

NCT07054801
View directory record Official record
Conditions
Headaches Associated With Subarachnoid Hemorrhage (SAH)
Interventions
Lidocaine hydrochloride, Methylprednisolone sodium succinate
Drug
Lead sponsor
Daniel Raper, MBBS
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 21, 2026, 4:47 AM EDT
Recruiting Not applicable Interventional

Aesthetic Outcome of Intra-dermal Versus Transcutaneous Purse-string Closure

NCT06448481
View directory record Official record
Conditions
Scarring
Interventions
Intra-dermal purse-string closure, Transcutaneous purse-string closure
Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 21, 2026, 4:47 AM EDT
Completed Phase 1 Interventional

Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin

NCT03259581
View directory record Official record
Conditions
Hepatocellular Carcinoma, Bilirubinemia
Interventions
Transarterial chemoembolization
Combination Product
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 21, 2026, 4:47 AM EDT
Completed Phase 4 Interventional Results available

Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT01543828
View directory record Official record
Conditions
COPD
Interventions
indacaterol, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
6
States / cities
Fullerton, California • Saint Charles, Missouri • Charlotte, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated May 10, 2013 · Synced Oct 21, 2026, 4:47 AM EDT
Completed Not applicable Interventional

Study to Look at Benefit of Surgical Drainage Before Beginning Medical Therapy for Crohns Perianal Fistulas

NCT01145365
View directory record Official record
Conditions
Crohns Disease, Fistula, Abscess
Interventions
Exam under anesthesia (EUA)
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Baltimore, Maryland • Pittsburgh, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 21, 2026, 4:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Deep Trigger Point Dry Needling on Strength Measurements of the Gluteus Medius Musculature

NCT03580200
View directory record Official record
Conditions
Trigger Point, Muscle Weakness
Interventions
Trigger Point Dry Needling
Other
Lead sponsor
Emily Slaven, PT, PhD
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 21, 2026, 4:47 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.

NCT07024407
View directory record Official record
Conditions
Heterotopic Ossification (HO)
Interventions
Andecaliximab
Drug
Lead sponsor
Ashibio Inc
Industry
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 21, 2026, 4:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment

NCT02581592
View directory record Official record
Conditions
Hepatic Impairment
Interventions
TD-4208
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 21, 2026, 4:47 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Pain Control After Lumbar Spine Fusion

NCT06484192
View directory record Official record
Conditions
Spine Fusion, NSAID (Non-Steroidal Anti-Inflammatory Drug), Postoperative Pain
Interventions
Naproxen 500 Mg, Ketorolac, OxyCODONE 5 mg Oral Tablet, Metaxalone 800 MG
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 21, 2026, 4:47 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

NCT00054236
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, filgrastim, cyclophosphamide, fludarabine phosphate, umbilical cord blood transplantation, methylprednisolone
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 120 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 21, 2026, 4:47 AM EDT
Completed No phase listed Observational

Bone Mineral Density in Women With Uterine Fibroids or Endometriosis

NCT03744507
View directory record Official record
Conditions
Uterine Fibroid, Endometriosis
Interventions
Not listed
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
660 participants
Timeline
2018 – 2020
U.S. locations
37
States / cities
Mobile, Alabama • Mesa, Arizona • Huntington Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 21, 2026, 4:47 AM EDT
Not listed Phase 2 Interventional

Evaluating Efficacy of the Dexmedetomidine Transdermal System for Postoperative Analgesia Following Abdominoplasty

NCT04242407
View directory record Official record
Conditions
Pain, Postoperative
Interventions
DMTS, Placebo
Drug
Lead sponsor
Teikoku Pharma USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Phoenix, Arizona • Bellaire, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 21, 2026, 4:47 AM EDT
Not listed No phase listed Observational

Cure Cystinosis International Registry

NCT01327807
View directory record Official record
Conditions
Cystinosis, Nephropathic Cystinosis, Renal Fanconi Syndrome
Interventions
Not listed
Lead sponsor
Cystinosis Research Foundation
Other
Eligibility
Not listed
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 21, 2026, 4:47 AM EDT
Not listed No phase listed Observational

Phase I/II Study of Neuroendocrine Dysfunction in Patients With Closed Head Injuries

NCT00006271
View directory record Official record
Conditions
Brain Injury
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
2
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 4:47 AM EDT
Completed Phase 1 Interventional

The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies

NCT01393509
View directory record Official record
Conditions
Metastatic Solid Tumor, Lymphoma, Myeloproliferative Neoplasms (MPN)
Interventions
PU-H71
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 21, 2026, 4:47 AM EDT
Completed Not applicable Interventional

Impact of Cognitive Behavioral Therapy on PTSD-CVD Link

NCT06429293
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Cognitive processing therapy
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 21, 2026, 4:47 AM EDT
Recruiting Phase 2 Interventional

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

NCT06526793
View directory record Official record
Conditions
B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
Interventions
Surovatamig
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
22
States / cities
Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 21, 2026, 4:47 AM EDT
Completed Not applicable Interventional

Functional Electrical Stimulation for Individuals With Secondary Progressive Multiple Sclerosis

NCT01647321
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
Active cycling, Passive cycling
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 68 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 21, 2026, 4:47 AM EDT
Recruiting Phase 2 Interventional

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

NCT05530421
View directory record Official record
Conditions
Relapsed and Refractory Multiple Myeloma
Interventions
Selinexor, Venetoclax, Dexamethasone
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
3
States / cities
Coral Gables, Florida • Deerfield Beach, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 21, 2026, 4:47 AM EDT
Recruiting No phase listed Observational

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

NCT00923507
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma, Monoclonal B-Cell Lymphocytosis, Small Lymphocytic Lymphoma, CLL (Chronic Lymphocytic Leukemia)
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 110 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 4:47 AM EDT
Withdrawn Phase 2 Interventional

Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma

NCT00621036
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer
Interventions
autologous immunoglobulin idiotype-KLH conjugate vaccine, sargramostim, methotrexate, thiotepa, radiation therapy
Biological · Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Oct 21, 2026, 4:47 AM EDT
Withdrawn Early Phase 1 Interventional

Comparison of Ventricular Tachycardia Ablation Strategies in Patients With Ischemic Cardiomyopathy

NCT04512911
View directory record Official record
Conditions
Ventricular Tachycardia
Interventions
Endocardial ablation, Endocardial- Epicardial ablation, Antiarrhythmic medications
Procedure · Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 21, 2026, 4:47 AM EDT